肝细胞癌：索拉非尼：年龄不再是问题。
Hepatocellular carcinoma: sorafenib: for once age is not an issue.
机构信息
University Clinic of Visceral Surgery and Medicine, Department of Hepatology, Inselspital, CH-3010 Bern, Switzerland.
出版信息
Nat Rev Gastroenterol Hepatol. 2014 May;11(5):273-4. doi: 10.1038/nrgastro.2014.48. Epub 2014 Apr 1.
PMID:24686265
Abstract
Are some patients with hepatocellular carcinoma just too old to be treated? More specifically, should the age of a patient influence the way sorafenib is prescribed? A new study has tried to address these questions, providing helpful information to guide clinicians making these decisions.
摘要
一些肝细胞癌患者是否太老而无法治疗？更具体地说，患者的年龄是否会影响索拉非尼的处方方式？一项新的研究试图解决这些问题，为指导临床医生做出这些决策提供了有帮助的信息。
Zotero 插件